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TACROLIMUS has been shown to be a safe and 
effective immunosuppressive agent in adult renal 
transplantation with significant advantages, including the 
ability to taper corticosteroids in up to 65% of recipients. 1-4 
The use of this agent in the pediatric population is less well 
described. We and others have previously reported that its 
use in pediatric patients is associated with excellent patient 
and graft survival results in a relatively small number of 
patients.5- 9 Here we report our expanded experience on the 
use of tacrolimus in pediatric renal transplantation. 
PATIENTS AND METHODS 
Between December 1989 and December 1996, 82 pediatric renal 
transplants were performed using tacrolimus-based immunosup-
pression without antilymphocyte antibody induction therapy. The 
mean age of the recipients was 10.6 :t 5.2 years (range 0.7 to 17.9 
years). More than one-quarter of patients could be categorized as 
'high-risk' with 18 (22%) cases being retransplantations and 6 
(7%) patients having panel reactive antibody (PRA) levels ~4M%K 
A total of 34 (41%) cases were with living donors and 48 (59%) 
were with cadaveric donors. with a mean donor age of 27.3 :t 14.6 
years (range 0.7 to 50 years), and a mean cold ischemia time in the 
cadaveric cases of 26.5 :t 8.8 hours. The mean number of HLA 
matches and mismatches was 2.8 :t 1.2 and 2.9 :t 1.3. respectively. 
and there were five (6%) O-antigen mismatches. The mean dura-
tion of follow-up was 4.0 :t 0.2 years (range 0.6 to 7.5 years). 
Immunosuppression consisted of a 0.15 mg/kg oral dose of tacroli-
mus preoperatively. with postoperative administration at 0.05 to 
0.10 mg/kg as a continuous intravenous infusion. Patients were 
subsequently converted to oral administration of tacrolimus at a 
dose of 0.15 mg/kg twice daily. The dose of tacroJimus was adjusted 
according to target whole blood trough levels. The levels aimed for 
were 20 to 25 nglmL during the first 2 weeks. 15 to 20 ng/mL at 1 
month. 10 to 15 nglmL at 3 months. and <5 to 8 to 9 ng/mL over 
the long term. Patients also received tapered corticosteroid ther-
apy. the aim being to withdraw corticosteroids completely by month 
6. 
RESULTS 
One- <lnd 4-year actuarial patient survival was 99% and 
94%. and actuarial graft survival was 98% and 84%. respec-
tively (Table I). There was no significant difference in 
patient and graft survival between the living donor and 
cadaveric donor recipients. However. 4-year graft survival 
was significantly higher in patients receiving a primary 
transplant compared with retransplant patients (P < .02). 
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Table 1. One- and 4-Year Patient and Graft Survival Rates in 
Tacrolimus-Treated Pediatric Renal Transplant Recipients 
1 Year 4 Years 
Actuarial patient survival (%) 99 94 
Actuarial graft survival (%) 98 84 
Uving donor (n = 34) 100 96 
Cadaver donor (n = 48) 86 81 
First transplant (n = 64) 100 90· 
Retransplant (n = 18) 89 66 
PRA <40% (n = 76) 99 8rt 
PRA ~4M% (n = 6) 86 57 
'p < .02 versus retransplant group. P < .03 versus PRA 2:40% group. 
PRA levels were also a prognostic indicator of graft sur-
vival, with 87% 4-year survival in those with levels <40% 
and 57% in patients with levels 2:40% (P < .03). Causes of 
graft loss included rejection (n = 5). disease recurrence 
(n = 5), pancreatitis (n = 2), infection (n = 1), and 
noncompliance (n = 1). 
The mean serum creatinine level was 1.1 ~ 0.5 mg/dL, 
and the corresponding calculated creatinine clearance was 
88 ~ 25 mUmin per 1.73 m2• Overall. prednisone was 
withdrawn in 66% of successfully transplanted patients at 
the 4-year follow-up time point. The mean dose of tacroli-
mus at this time was 0.18 :t 0.12 mg/kg/d. with mean levels 
of 9.9 ~ 4.6 ng/mL. The overall dose of corticosteroids was 
0.04 :t 0.09 mglkg/d, while the mean dose in patients 
remaining on corticosteroids was 0.17 :t 0.11 mg/kg/d. In 
the corticosteroid-free children. the mean standard devia-
tion height scores (Z score) at the time of transplantation, 
and at 1 and 4 years, were -2.3 :t 2.0, -1.7 ~ 1.0, and 
+0.36 :t 1.5, respectively, showing an improvement over 
time with corticosteroid dose reduction and subsequent 
withdrawal. In those remaining on corticosteroids, the 
mean Z scores at 1 and 4 years were - 2.0 ~ 1.1 and -0.6 :t 
2.9, respectively. Furthermore. 86% of the successfully 
transplanted patients were not taking any antihypertensive 
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medications. Mean cholesterol levels were also within the 
acceptable range, at 155 ± 31 mgldL. 
Incidence of Rejection 
Although the overall incidence of acute rejection was 44%, 
there was a clear reduction in rejection episodes over time 
as greater experience was gained in the use of tacrolimus. 
Between December 1989 and December 1993, the inci-
dence of acute rejection was 63%, but was significantly 
reduced to 23% (P = .0003) between January 1994 and 
December 1996. The incidence of both corticosteroid-
resistant rejection and delayed graft function was 5%. A 
total of 2% of patients with delayed graft function required 
dialysis within 1 week of transplantation. 
Infection 
The overall incidence of cytomegalovirus infection (CMV) 
was 13%. Again, a decreased incidence of CMV was 
observed over time. with 17% of patients being affected 
between December 1989 and December 1992, which was 
reduced to 12% during the subsequent 4 years. 
DISCUSSION 
There has been relatively little experience with the use of 
tacrolimus in pediatric renal transplantation including re-
ports from our own institution5- 8 •10 as well as the University 
of Minnesota II and Johns Hopkins Hospital9 describing 
excellent patient and graft survival results in the short term. 
We currently report patient and graft survival results of 
99% and 94% after 1 year and 98% and 84% after 4 years, 
with excellent renal function and the ability to taper corti-
costeroids in the majority of children. One concern with the 
use of tacrolimus in children has been the relatively high 
incidence of Epstein-Barr virus (EBV)-related posttrans-
plant Iymphoproliferative disorder (PTLD) which in the 
early part of this series was 17% (December 1989 to 
December 1992.5 cases in 29 patients). However. in the 
latter part of this series (January 1993 to December 1996) 
the incidence had decreased to 4% (2 cases in 53 patients). 
All of these cases responded to temporary discontinuation 
of immunosuppression and intravenous ganciclovir and 
there were no deaths or short-term graft losses. One patient 
lost the allograft because of chronic rejection 3 years after 
heing trcated for PTLD. This indicates that there is a 
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learning curve associated with the use of tacrolimus in the 
pediatric population. In EBV mismatched recipients we are 
currently following serial EBV polymerase chain reaction 
(peR) levels to allow early identification and the use of 
ganciclovir treatment in seroconverting children. In addi-
tion, we have become more judicious in the early reduction 
of tacrolimus levels in the postoperative period in this 
group of patients. We feel that these factors have led to the 
observed reduction in the incidence of PTLD in the latter 
part of our series. The early incidence of insulin-dependent 
posttransplant diabetes mellitus (PTDM) was 9% in suc-
cessfully transplanted patients, but with reduction of 
tacrolimus doses and corticosteroid tapering the final 
incidence was only 1 %. The significant benefits in this 
series have been the gratifying improvements in growth 
as reflected by improved mean standard deviation height 
scores in children who were able to be weaned off 
corticosteroids. 
CONCLUSION 
These data demonstrate the efficacy of tacrolimus-based 
immunosuppression in pediatric renal transplant recipients, 
with reasonable patient and graft survival, routine achieve-
ment of corticosteroid and antihypertensive medication 
withdrawal, and gratifying increases in growth. 
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